GlassScriptPhysician profile
Earl R Stoddard
NPI 1760400238
$3,141.11
in general payments reported to CMS, 2019-2025
24 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $481 · 2021: $346 · 2022: $505 · 2023: $258 · 2024: $517 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.49 | 2019-2025 | Skyrizi, Rinvoq |
| Merz North America, INC. | $426.28 | 2019-2025 | |
| Janssen Biotech, INC. | $278.66 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $191.05 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $180.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $170.17 | 2022-2025 | Dupixent |
| Ucb, INC. | $125.45 | 2021-2024 | Bimzelx |
| Leo Pharma INC. | $118.55 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $105.97 | 2019-2024 | Olumiant, Taltz |
| Biofrontera INC. | $77.30 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $54.97 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $53.96 | 2021 | |
| Genzyme Corporation | $49.65 | 2019-2024 | |
| Pfizer INC. | $29.20 | 2020 | |
| Prugen, INC. Pharmaceuticals | $25.50 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $25.45 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.55 | 2023 | Cyltezo |
| Organogenesis INC. | $19.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2024 | Sotyktu |
| Fresenius Kabi USA, LLC | $16.33 | 2024 | Idacio |
| Incyte Corporation | $15.93 | 2024 | Opzelura |
| Boston Scientific Corporation | $15.25 | 2025 | Intracept |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.31 | 2020 | |
| Amgen INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.